NephroGenex Announces Closing Of Initial Public Offering

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its initial public offering of 3,100,000 shares of common stock at a public offering price of $12.00 per share for total gross proceeds of $37,200,000 before underwriting discounts. In addition, NephroGenex has granted the underwriter a 45-day option to purchase up to an additional 465,000 shares of common stock from NephroGenex to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.